SERA PROGNOSTICS, INC.
No enriched coverage for $SERA in the last 7 days.
No SEC Form 4 filings for $SERA in the last 30 days.
See all $SERA insider activity →Sera Prognostics (Nasdaq: SERA) reported a PRIME trial subgroup analysis in first-time pregnancies (n=1,783). According to the company, PreTRM Test-guided care reduced NICU admissions by 22% versus routine care and lowered severe composite morbidity (6.4% vs 9.1%). The study also cited 28 screenings to prevent one NICU admission.
SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001534969 0001534969 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
Whetstone Capital Advisors, LLC and David Atterbury have amended their stake in Sera Prognostics (NASDAQ: SERA), now reporting beneficial ownership of 3,306,889 shares of Class A Common Stock, which represents 8.6% of the class. This update was disclosed in a Schedule 13G/A filing with the SEC, indicating shared voting and dispositive power over these shares. The filing, signed on May 1, 2026, reflects a passive investment and transparency regarding their holdings.
Recent SERA coverage spans financial news, technology and corporate actions.
The publication adds clinical efficacy evidence for PreTRM in a key underserved subgroup, supporting adoption and payer/provider confidence.
Board/compensation committee refresh is unlikely to change near-term fundamentals, but it can affect governance expectations and sentiment.
Institutional investors Whetstone Capital Advisors and David Atterbury have increased their stake in Sera Prognostics to 8.6%, indicating a potential positive outlook or confidence in the company's prospects.
Sera Prognostics (SERA) is currently undervalued with a significant analyst price target indicating potential upside. However, low revenue, unprofitability, and insider selling pose risks. The stock has underperformed relative to industry and market benchmarks, suggesting caution.
The upgrade to a Buy rating suggests increased analyst confidence, potentially leading to short-term price appreciation.
alphai scores every news story that mentions SERA with an AI model for sentiment and relevance, and aggregates insider trades from SERA PROGNOSTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sera Prognostics (Nasdaq: SERA) reported a PRIME trial subgroup analysis in first-time pregnancies (n=1,783). According to the company, PreTRM Test-guided care reduced NICU admissions by 22% versus routine care and lowered severe composite morbidity (6.4% vs 9.1%). The study also cited 28 screenings to prevent one NICU admission.
3 min readSERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001534969 0001534969 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,
2 min readWhetstone Capital Advisors, LLC and David Atterbury have amended their stake in Sera Prognostics (NASDAQ: SERA), now reporting beneficial ownership of 3,306,889 shares of Class A Common Stock, which represents 8.6% of the class. This update was disclosed in a Schedule 13G/A filing with the SEC, indicating shared voting and dispositive power over these shares. The filing, signed on May 1, 2026, reflects a passive investment and transparency regarding their holdings.
2 min readThis Simply Wall St analysis provides a comprehensive overview of Sera Prognostics (SERA), a women's health company. It details SERA's market capitalization, current stock price, analyst price target of US$5 (indicating 60.6% undervaluation), and a risk analysis highlighting low revenue, unprofitability, and insider selling. The report also covers the company's fundamentals, recent news, and price performance, noting its underperformance compared to the US Biotechs industry and the broader US market over the past year.
4 min readSera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min readSera Prognostics (SERA) delivered earnings and revenue surprises of +15.79% and -75.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
4 min readSera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near ...
3 min readSera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
3 min read
